• Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021

  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Thursday July 15th 2021

  • Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

    Monday July 12th 2021

  • imec’s ultrasound sensor technology yields accurate pulse wave velocity and blood pressure values

    Tuesday June 29th 2021

  • OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday June 8th 2021

  • Sequana Medical announces first patient enrolled in SAHARA DESERT

    Tuesday June 1st 2021

  • Mithra announces European approval of Estelle®

    Friday May 21st 2021

  • Eurofins Genomics meets global demand for SARS-CoV-2 full genome sequencing, with over 100,000 sequenced samples in less than 8 weeks

    Thursday May 20th 2021

  • Your news here?

  • Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

    Wednesday May 19th 2021

  • Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme

    Tuesday May 11th 2021

  • miDiagnostics accelerates with launch of rapid COVID-19 PCR test product

    Monday May 3rd 2021


Strategic Partners